C Frank Bennett

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2340677/publications.pdf

Version: 2024-02-01

39	12,823	87888 38	315739 38
papers	citations	h-index	g-index

39	39	39	10930
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2017, 377, 1723-1732.	27.0	1,533
2	RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform. Annual Review of Pharmacology and Toxicology, 2010, 50, 259-293.	9.4	1,136
3	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2018, 378, 625-635.	27.0	977
4	Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet, The, 2016, 388, 3017-3026.	13.7	801
5	RNA Toxicity from the ALS/FTD C9ORF72 Expansion Is Mitigated by Antisense Intervention. Neuron, 2013, 80, 415-428.	8.1	785
6	Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis. Neuron, 2012, 74, 1031-1044.	8.1	635
7	An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurology, The, 2013, 12, 435-442.	10.2	534
8	Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4530-9.	7.1	508
9	Results from a phase 1 study of nusinersen (ISIS-SMN _{Rx}) in children with spinal muscular atrophy. Neurology, 2016, 86, 890-897.	1.1	506
10	Targeting Huntingtin Expression in Patients with Huntingtonâ€™s Disease. New England Journal of Medicine, 2019, 380, 2307-2316.	27.0	493
11	Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy. Science Translational Medicine, 2011, 3, 72ra18.	12.4	437
12	Antisense oligonucleotide therapy for neurodegenerative disease. Journal of Clinical Investigation, 2006, 116, 2290-2296.	8.2	425
13	Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Research, 2007, 35, 687-700.	14.5	361
14	Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Science Translational Medicine, 2017, 9, .	12.4	354
15	Phase 1â€“2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. New England Journal of Medicine, 2020, 383, 109-119.	27.0	354
16	Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nature Neuroscience, 2019, 22, 180-190.	14.8	345
17	Antisense oligonucleotide therapy for spinocerebellar ataxia type 2. Nature, 2017, 544, 362-366.	27.8	263
18	Potent and Selective Antisense Oligonucleotides Targeting Single-Nucleotide Polymorphisms in the Huntington Disease Gene / Allele-Specific Silencing of Mutant Huntingtin. Molecular Therapy, 2011, 19, 2178-2185.	8.2	246

#	Article	IF	Citations
19	Pharmacology of a Central Nervous System Delivered 2â€²-O-Methoxyethylâ€“Modified Survival of Motor Neuron Splicing Oligonucleotide in Mice and Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 46-55.	2.5	238
20	Antisense Oligonucleotide Therapies for Neurodegenerative Diseases. Annual Review of Neuroscience, 2019, 42, 385-406.	10.7	214
21	Nusinersen in later-onset spinal muscular atrophy. Neurology, 2019, 92, e2492-e2506.	1.1	183
22	Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. Journal of Clinical Investigation, 2018, 128, 3558-3567.	8.2	171
23	Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Research, 2013, 41, 9634-9650.	14.5	138
24	Allele-Selective Inhibition of Mutant Huntingtin Expression with Antisense Oligonucleotides Targeting the Expanded CAG Repeat. Biochemistry, 2010, 49, 10166-10178.	2.5	127
25	Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine, 2012, 18, 634-643.	6.7	116
26	Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1. Journal of Pharmacology and Experimental Therapeutics, 2015, 355, 329-340.	2.5	106
27	DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nature Communications, 2015, 6, 7969.	12.8	99
28	Allele-Specific Suppression of Mutant Huntingtin Using Antisense Oligonucleotides: Providing a Therapeutic Option for All Huntington Disease Patients. PLoS ONE, 2014, 9, e107434.	2.5	92
29	Huntingtin suppression restores cognitive function in a mouse model of Huntingtonâ€™s disease. Science Translational Medicine, 2018, 10, .	12.4	89
30	Cholesterol-functionalized DNA/RNA heteroduplexes cross the bloodâ€“brain barrier and knock down genes in the rodent CNS. Nature Biotechnology, 2021, 39, 1529-1536.	17.5	75
31	Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice. Molecular Therapy - Nucleic Acids, 2017, 7, 465-474.	5.1	71
32	Nuclear accumulation of CHMP7 initiates nuclear pore complex injury and subsequent TDP-43 dysfunction in sporadic and familial ALS. Science Translational Medicine, 2021, 13, .	12.4	68
33	Antisense oligonucleotides targeting mutant Ataxin-7 restore visual function in a mouse model of spinocerebellar ataxia type 7. Science Translational Medicine, 2018, 10, .	12.4	63
34	Î±-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinsonâ€™s disease. JCI Insight, 2021, 6, .	5.0	60
35	Antisense Oligonucleotide-Based Therapies for Diseases Caused by pre-mRNA Processing Defects. Advances in Experimental Medicine and Biology, 2014, 825, 303-352.	1.6	60
36	Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease. Journal of Huntington's Disease, 2013, 2, 217-228.	1.9	58

#	Article	IF	Citations
37	Antisense Drugs Make Sense for Neurological Diseases. Annual Review of Pharmacology and Toxicology, 2021, 61, 831-852.	9.4	54
38	Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates. Nucleic Acids Research, 2019, 47, 6045-6058.	14.5	48
39	Antisense oligonucleotide drugs for neurological and neuromuscular disease. , 2020, , 221-245.		0